GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (FRA:AB3A) » Definitions » Net Interest Income

Sarepta Therapeutics (FRA:AB3A) Net Interest Income : €48 Mil (TTM As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. Sarepta Therapeutics's net interest income for the three months ended in Dec. 2023 was €16 Mil. Its net interest income for the trailing twelve months (TTM) ended in Dec. 2023 was €48 Mil.

Sarepta Therapeutics Net Interest Income Historical Data

The historical data trend for Sarepta Therapeutics's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Net Interest Income Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -21.09 -46.84 -55.77 -24.10 58.65

Sarepta Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.37 12.14 2.95 16.49 15.95

Sarepta Therapeutics Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Net Interest Income Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Sarepta Therapeutics (FRA:AB3A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (FRA:AB3A) » Definitions » Net Interest Income
Comparable Companies
RPRX INCY UTHR TECH BMRN ROIV LEGN VKTX CERE ASND OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
SRPT:USA AB3A:Germany S1RP34:Brazil
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Website
https://www.sarepta.com
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (FRA:AB3A) Headlines

No Headlines